Vyne Net Interest Income from 2010 to 2026
| VYNE Stock | USD 0.60 0.01 1.69% |
Net Interest Income | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 2.1 M |
Check Vyne Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vyne Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 13 M, Selling General Administrative of 25.5 M or Other Operating Expenses of 63.3 M, as well as many indicators such as Price To Sales Ratio of 226, Dividend Yield of 0.0 or PTB Ratio of 2.59. Vyne financial statements analysis is a perfect complement when working with Vyne Therapeutics Valuation or Volatility modules.
Vyne | Net Interest Income | Build AI portfolio with Vyne Stock |
Analyzing Vyne Therapeutics's Net Interest Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Interest Income has evolved provides context for assessing Vyne Therapeutics's current valuation and future prospects.
Latest Vyne Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Vyne Therapeutics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Vyne Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vyne Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Vyne Net Interest Income Regression Statistics
| Arithmetic Mean | (118,000) | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | (1,738) | |
| Mean Deviation | 1,148,706 | |
| Median | 264,000 | |
| Standard Deviation | 2,050,263 | |
| Sample Variance | 4.2T | |
| Range | 8.7M | |
| R-Value | (0.20) | |
| Mean Square Error | 4.3T | |
| R-Squared | 0.04 | |
| Significance | 0.45 | |
| Slope | (80,461) | |
| Total Sum of Squares | 67.3T |
Vyne Net Interest Income History
About Vyne Therapeutics Financial Statements
Vyne Therapeutics stakeholders use historical fundamental indicators, such as Vyne Therapeutics' Net Interest Income, to determine how well the company is positioned to perform in the future. Although Vyne Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vyne Therapeutics' assets and liabilities are reflected in the revenues and expenses on Vyne Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vyne Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:Check out the analysis of Vyne Therapeutics Correlation against competitors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Will Biotechnology sector continue expanding? Could Vyne diversify its offerings? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Vyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.78) | Revenue Per Share | Quarterly Revenue Growth 0.397 | Return On Assets | Return On Equity |
Understanding Vyne Therapeutics requires distinguishing between market price and book value, where the latter reflects Vyne's accounting equity. The concept of intrinsic value - what Vyne Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Vyne Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vyne Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.